← Eichor
Study identifier: NCT06728436 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

Condition: Alzheimer Disease  ·  Sponsor: University of Kansas Medical Center

PhaseNA
Planned participants288
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersYes

About this study

The goal of this randomized clinical trial it to test the efficacy of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences . Participants will receive a variety of text messages, from automatic to keyword-drive, regarding ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Participants will also complete measures regarding depressive symptoms, coping, behavioral symptoms, and preparedness for caregiving.

This description comes directly from the study's public registry record.

Talk to the study team

Rachel Ruiz  ·  913-945-5052  ·  rruiz3@kumc.edu

Jaime Perales Puchalt, PhD, MPH  ·  913-588-3716  ·  jperales@kumc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Kansas Medical CenterFairway, Kansas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06728436